Company / SG&A Expense
Amylyx Pharmaceuticals, Inc. SG&A Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$62.9M
FY2025
5-year range
$38.9M / $188.4M
FY2021-FY2025
Trend
-45.0%
vs FY2024
Sector context
#143 of 213
Health Care
What the data says
At $63M, Amylyx Pharmaceuticals, Inc.'s sg&a expense ranks #71 of 213 in the Health Care sector. Improved from $188M to $63M over the past 2 years.
Based on SEC 10-K filings.
$63M in FY2025 with a 3-year CAGR of -20.9%.
Improved from $188M to $63M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -20.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#71 of 213 in Health CareTop 33% of 213This company $62.9M Sector average $722.3M
▼
-91.3% below sector average
Key checks
Key Insights
- 3-year CAGR of -20.9%, indicating a declining trend.
- In FY2025, sg&a expense decreased 45.0% year-over-year.
- Ranks #143 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $62.9M | -45.0% |
| FY2024 | $114.3M | -39.3% |
| FY2023 | $188.4M | +48.2% |
| FY2022 | $127.1M | +226.5% |
| FY2021 | $38.9M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026